Global oncology revenue by top ten pharmaceutical companies 2017 and 2024
The top ten pharmaceutical companies based on global oncology revenue in 2017 and the projected revenue of those top 10 companies in 2024 include Roche, Celgene and Bristol-Meyers Squibb, to name a few. At that time Roche was estimated to be the top pharmaceutical company based on oncology revenue. Roche’s oncology products generated an estimated 27.5 billion U.S. dollars in 2017. It is expected that Roche’s oncology products will generate 27.8 billion U.S. dollars by 2024.
Oncology pharmaceuticals
Among U.S. oncology brands in 2016, Clegene’s Revlimid was the top revenue generating oncology brand. Revlimid is a drug used to treat multiple myeloma, myelodysplastic syndromes and mantel cell lymphoma. Globally, Revlimid was also among the top oncology products in 2017. However, it is expected to be surpassed by Merck & Co.’s Keytruda by 2024. This data reveals the current existing oncologics, however, there are many new drugs in development. In the U.S., it was expected that 2018 will yield the largest number of cancer drugs in development in recent history.
Cancer prevalence and treatments
The U.S. and Europe have the highest prevalence of diagnosed cancer cases globally as of 2018. Among all types of cancer, trachea, bronchus and lung cancer are the deadliest, followed by liver cancer. The availability of cancer treatments varies around the world. As of 2017, the U.S. and Germany had the largest number of new medications for cancer available between 2012 and 2016. At that same time, China and India had only smaller number of cancer drugs available.
Oncology pharmaceuticals
Among U.S. oncology brands in 2016, Clegene’s Revlimid was the top revenue generating oncology brand. Revlimid is a drug used to treat multiple myeloma, myelodysplastic syndromes and mantel cell lymphoma. Globally, Revlimid was also among the top oncology products in 2017. However, it is expected to be surpassed by Merck & Co.’s Keytruda by 2024. This data reveals the current existing oncologics, however, there are many new drugs in development. In the U.S., it was expected that 2018 will yield the largest number of cancer drugs in development in recent history.
Cancer prevalence and treatments
The U.S. and Europe have the highest prevalence of diagnosed cancer cases globally as of 2018. Among all types of cancer, trachea, bronchus and lung cancer are the deadliest, followed by liver cancer. The availability of cancer treatments varies around the world. As of 2017, the U.S. and Germany had the largest number of new medications for cancer available between 2012 and 2016. At that same time, China and India had only smaller number of cancer drugs available.
